Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | Self administered glucagon | Exercise-Induced Hypoglycemia | Phase 2b | Trial Discontinued | Intranasal or subcutaneous | Endocrinology |
| Xeris Biopharma Holdings Inc. | Continuous glucagon | Hypoglycemia-Associated Autonomic Failure | Phase 2a | Trial Discontinued | Subcutaneous | Endocrinology |
| XOMA Royalty Corporation | Seralutinib (GB002) - (TORREY/PROSERA) | Pulmonary arterial hypertension (PAH) | Phase 3 | Enrollment Conclusion | Inhalation | Cardiology |
| XOMA Royalty Corporation | RZ358 | Hypoglycemia in patients with tumor hyperinsulinism (HI) | Phase 3 | IND Clearance | Intravenous | Endocrinology |
| XOMA Royalty Corporation | Mezagitamab (TAK-079) - (TAK-079-1004) | Primary Immune Thrombocytopenia | Phase 3 | Enrollment Initiation | Intravenous | Hematology |
| XOMA Royalty Corporation | HIL-214 - (NEST-IN1) | Prevention of Norovirus-Related Acute Gastroenteritis in Infants | Phase 2b | Trial Discontinued | Oral | Gastroenterology |
| XOMA Royalty Corporation | RZ358 - (sunRIZE) | Congenital hyperinsulinism (HI), non-islet cell tumors (NICTs) that have uncontrolled hypoglycemia | Phase 2b | Data Released | Intravenous | Endocrinology |
| XOMA Royalty Corporation | Nemvaleukin + KEYTRUDA (pembrolizumab) - (ION-01) | Recurrent or metastatic head and neck squamous cell carcinoma | Phase 2 | Data Released | Intravenous | Oncology |
